PROTAGONIST THERAPEUTICS,INC. (NASDAQ:PTGX) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure.
On November27, 2018, Protagonist Therapeutics,Inc. (the “Company”) issued a press release announcing a new development candidate, PN-10943. A copy of the press release is attached hereto as Exhibit99.1.
On November27, 2018, the Company held a conference call to discuss the new development candidate, PN-10943. The conference call was accompanied by a presentation, a copy of which is attached hereto as Exhibit99.2.
The information in this Current Report on Form8-K, including the attached Exhibits 99.1 and 99.2, is being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form8-K.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
Protagonist Therapeutics, Inc ExhibitEX-99.1 2 a18-40738_1ex99d1.htm EX-99.1 Exhibit 99.1 Protagonist Therapeutics Announces New Development Candidate PN-10943 for the Treatment of Inflammatory Bowel Disease Oral,…To view the full exhibit click here
About PROTAGONIST THERAPEUTICS,INC. (NASDAQ:PTGX)
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn’s disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.
